After Needham and Mizuho Securities gave Autolus Therapeutics (NASDAQ: AUTL) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Matt Phipps maintained a Buy rating on Autolus Therapeutics yesterday. The company’s shares closed last Wednesday at $10.25.
According to TipRanks.com, Phipps is a 1-star analyst with an average return of -0.6% and a 41.3% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $25.00, representing a 137.6% upside. In a report issued on November 30, Needham also assigned a Buy rating to the stock with a $26.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.19 and a one-year low of $3.00. Currently, Autolus Therapeutics has an average volume of 77.61K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
